Analyst consensus rating

Enliven Therapeutics Analyst Rating: Strong Buy

Direct answer

Enliven Therapeutics's consensus rating is Strong Buy.

12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $74.33.
Forecast evidence checked November 21, 2026.

Get free Enliven Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$46.53
Average price target
$74.33
High price target
$82.00
Low price target
$69.00
Low target gap
+48.3%
Target upside
+59.8%
High target gap
+76.2%
Target range width
27.9%
Consensus rating
Strong Buy
Analysts
12
Evidence date
November 21, 2026
Valid through
November 28, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Enliven Therapeutics?

Enliven Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $74.33.

How far are Enliven Therapeutics's low and high targets from the recorded price?

The low target implies +48.3%, while the high target implies +76.2%.

How many analysts are included in Enliven Therapeutics's consensus?

The verified consensus includes 12 analysts.

How is Enliven Therapeutics's target upside or downside calculated?

The average target of $74.33 is divided by the recorded price of $46.53, then one is subtracted to produce +59.8%. This does not guarantee a future return.

When was Enliven Therapeutics's analyst forecast verified?

The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.